Top Markets
#1 TENDIES TENDIES +60.15%
#2 Threshold Network Threshold Network +48.72%
#3 Akedo Akedo +24.88%
#4 Cash Cat Cash Cat +21.86%
#5 Kinetiq Kinetiq +16.38%
#6 OSK OSK +16.37%
#7 Maple Finance Maple Finance +13.27%
#8 Ape and Pepe Ape and Pepe +12.62%
#9 Magma Finance Magma Finance +12.46%
#10 Falcon Finance Falcon Finance +11.62%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD
Rank in Stocks #17262
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Share Price
$0.8799
Last synced: 2026-09-01
Market Cap
$259.22M
Change (1 day)
-7.85%
Change (1 year)
-14.57%
Country
US
Trade Invivyd, Inc. (IVVD)

Category

Healthcare
P/E ratio for Invivyd, Inc. (IVVD)
P/E ratio as of 2026 TTM: 0
According to Invivyd, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Invivyd, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.